2026-06-15

Platinum volume spike - 4.0× the 20-day average (53 vs 13 avg)

OSINT: SpaceX Valuation Hits $2.5T, Becomes World’s 6th Largest Public Company

OSINT: Trump arrives in Geneva for G7 summit

OSINT: Israel Says Not Bound by Lebanon Clause, Tells Trump

CFTC BITCOIN speculator at extreme long - contrarian bear signal

CFTC SILVER speculator at extreme short - contrarian bull signal

CFTC NATURAL GAS speculator at extreme long - contrarian bear signal

OSINT: Iran claims military gains secured US MOU

RBOB Gasoline bear 5.0% vs prior close ($3.05 → $2.90)

Cotton bull 4.9% vs prior close ($72.94 → $76.50)

WTI Crude Oil bear 4.5% vs prior close ($84.88 → $81.04)

Cocoa bull 5.8% vs prior close ($3,779.00 → $3,998.00)

Heating Oil bear 5.5% vs prior close ($3.40 → $3.22)

OSINT: S&P 500 jumps 1.7% on US‑Iran deal, adds $1.2 trn market cap

OSINT: Belarus Declares No Military Action Against Ukraine

NATURAL GAS - speculators net long (+2.3σ vs 52w mean) - contrarian bear signal

OSINT: Market Calendar Update for June 15, 2026

OSINT: Russia’s Kyiv Drone & Missile Strike Ignites Historic Dovzhenko Film Studio

Sugar No. 11 bull 3.4% vs prior close ($13.70 → $14.16)

Nasdaq E-mini bull 4.0% vs prior close ($29,662.00 → $30,846.75)

Platinum bull 3.7% vs prior close ($1,709.20 → $1,772.40)

Silver bull 3.3% vs prior close ($67.86 → $70.12)

SOL open interest -63.3% - OI collapse

ETH open interest -67.8% - OI collapse

BTC open interest +235.9% - OI surge

BTC open interest -49.0% - OI collapse

ETH open interest -66.2% - OI collapse

SOL open interest +47.0% - OI surge

SOL open interest -64.3% - OI collapse

BTC open interest -40.7% - OI collapse

ETH open interest -65.8% - OI collapse

BTC open interest +216.4% - OI surge

ETH open interest +221.9% - OI surge

SOL open interest +291.7% - OI surge

SPYx/USDC has $39.7M volume but only $782K liquidity - thin market, slippage risk

SOL/USDC crashed -50.2% in 24h on orca DEX

ETH DEX volume/liquidity ratio elevated (0.58x) - strong on-chain trading activity

OSINT: Solana Firm Turns Down Forward's Bid Amid Treasury Pressure

SOL DEX volume/liquidity ratio elevated (1.01x) - strong on-chain trading activity

ETH DEX volume/liquidity ratio elevated (0.52x) - strong on-chain trading activity

SOL DEX volume/liquidity ratio elevated (0.86x) - strong on-chain trading activity

BITCOIN - speculators net long (+2.5σ vs 52w mean) - contrarian bear signal

SOL DEX volume/liquidity ratio elevated (0.71x) - strong on-chain trading activity

OSINT: Trader 0xa2e8 nets $4.93M in 5 days on ETH, 90% win rate

Phase 3 trial terminated early - JOHNSON Treatment of Anemic Patients With Cancer Who Are Not Receiving Chemotherapy or R

Phase 3 trial terminated early - ELI A Comparison of Two Treatment Strategies in Older Participants With Type 2 Diabe

Phase 3 trial terminated early - ELI A Study of Evacetrapib (LY2484595) in Participants With High Cholesterol

Phase 3 trial terminated early - ELI A Rheumatoid Arthritis Study in Participants on a Background Treatment of Methot

Phase 3 trial terminated early - BIOGEN Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and P

Phase 3 trial terminated early - BIOGEN Natalizumab and Chronic Inflammation

Phase 3 trial terminated early - BIOGEN A Study to Investigate the Radiological Onset of Action After Treatment Initiati

Phase 3 trial terminated early - BIOGEN Corticosteroids for Immune Reconstitution Inflammatory Syndrome (IRIS)

Phase 3 trial terminated early - BIOGEN Bardoxolone Methyl in Patients With Connective Tissue Disease-associated Pulmona

Phase 3 trial terminated early - AMGEN Multicenter,Single-arm Study to Evaluate Efficacy, Safety, & Pharmacokinetics of

Phase 3 trial terminated early - AMGEN A Study of CAD106 and CNP520 Versus Placebo in Participants at Risk for the Onse

Phase 3 trial terminated early - AMGEN Effect of Darbepoetin Alfa (Aranesp®) on Anemia in Patients With Advanced Hormon

Phase 3 trial terminated early - AMGEN A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinic

Phase 3 trial terminated early - INCYTE A Study of Ruxolitinib in Pancreatic Cancer Patients

Phase 3 trial terminated early - INCYTE To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants W

Phase 3 trial terminated early - INCYTE To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participan

Phase 3 trial terminated early - Medtronic DIAM™ Spinal Stabilization System vs. Decompression, Formerly vs. Posterolateral

Phase 3 trial terminated early - Medtronic Diagnostic Outcome Trial in Heart Failure (DOT-HF Trial)

Phase 3 trial terminated early - Medtronic Condition of Approval Study

Phase 3 trial terminated early - AbbVie An Oral GnRH Antagonist to Treat Mild Autonomous Cortisol Excess (MACE) Due to A

Phase 3 trial terminated early - AbbVie Upadacitinib for Prurigo Nodularis

Phase 3 trial terminated early - ABBOTT Catheter Ablation Versus Amiodarone for Shock Prophylaxis in Defibrillator Patie

Phase 3 trial terminated early - ABBOTT Effects of a Supplement Enriched in Hydroxymethylbutyrate and Vitamin D on Muscl

Phase 3 trial terminated early - ABBOTT Comparative Study of the Effect of Ezetimibe Versus Extended-Release Niacin on A

Phase 3 trial terminated early - ABBOTT Study to Examine the Longer-Term Efficacy and Safety of Sibutramine Hydrochlorid

Phase 3 trial terminated early - ABBOTT Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular

Phase 3 trial terminated early - PFIZER Vaspect Study - An Open-Label Trial Of Donepezil in Vascular and Mixed Dementia

Phase 3 trial terminated early - PFIZER Desvenlafaxine for Treatment of Hot Flashes in Women With Breast Cancer Taking T

Phase 3 trial terminated early - PFIZER Strategy for Adequate Blood Pressure Lowering in the Patients With Intracranial

Phase 3 trial terminated early - GILEAD Study to Evaluate the Efficacy and Safety of Remdesivir in Participants With Sev

Phase 3 trial terminated early - GILEAD DORADO-EX: Long-Term Safety Extension Study to the Phase 3 DORADO Study (Protoco

Phase 3 trial terminated early - GILEAD Ambisome and Management of Culture-negative Neutropenic Fever Unresponsive to An

Phase 3 trial terminated early - GILEAD Value of Inhaled Treatment With Aztreonam Lysine in Bronchiectasis

Phase 3 trial terminated early - GILEAD Study of Cilofexor in Adults With Primary Sclerosing Cholangitis

Phase 3 trial terminated early - GILEAD Rapid Start vs. Standard Start Antiretroviral Therapy (ART) in HIV

5 congress members traded TSCO - net BEAR (0B/0S)

OSINT: Solana Firm Turns Down Forward's Bid Amid Treasury Pressure

OSINT: US Air Force B‑52 bomber crashes at Edwards AFB, crew status unknown

5 congress members traded TSCO - net BEAR (0B/0S)

Q1-2027: Beat consensus by 73.0% - EPS $-0.09 vs $-0.3333 estimate

Bond issued at elevated rate 4.75% - credit-stress signal

Bond issued at elevated rate 4.75% - credit-stress signal

Q3-2026: Missed consensus by 717.0% - EPS $-0.5 vs $-0.0612 estimate

Q1-2026: Missed consensus by 15.9% - EPS $-0.39 vs $-0.3366 estimate

Q4-2025: Missed consensus by 77.7% - EPS $-0.58 vs $-0.3264 estimate

Beat consensus by 198.0% - EPS $0.05 vs $-0.051 estimate

Q4-2026: Missed consensus by 140.9% - EPS $-0.23749 vs $-0.0986 estimate

Q4-2025: Missed consensus by 8.0% - EPS $2.63 vs $2.8583 estimate

Q2-2025: Missed consensus by 12.2% - EPS $0.63 vs $0.7177 estimate

Beat consensus by 8.2% - EPS $0.63 vs $0.582 estimate

Q4-2025: Beat consensus by 7.9% - EPS $0.69 vs $0.6396 estimate

Q3-2025: Beat consensus by 9.3% - EPS $0.79 vs $0.7225 estimate

Beat consensus by 21.6% - EPS $-0.4 vs $-0.51 estimate

Q1-2026: Missed consensus by 24.8% - EPS $-0.21 vs $-0.1683 estimate

Q4-2025: Beat consensus by 65.4% - EPS $-0.06 vs $-0.1734 estimate

Beat consensus by 47.2% - EPS $0.24 vs $0.163 estimate

Q3-2025: Missed consensus by 15.9% - EPS $0.58 vs $0.6894 estimate

Q1-2026: Beat consensus by 18.3% - EPS $0.5 vs $0.4228 estimate

Q4-2025: Beat consensus by 215.8% - EPS $0.15 vs $-0.1295 estimate

Q1-2026: Beat consensus by 21.4% - EPS $0.26 vs $0.2142 estimate

Q2-2025: Beat consensus by 13.8% - EPS $-0.5 vs $-0.5799 estimate

Q3-2025: Missed consensus by 19.6% - EPS $-0.67 vs $-0.5602 estimate

Missed consensus by 20.8% - EPS $-0.93 vs $-0.77 estimate

Q3-2025: Beat consensus by 19.9% - EPS $0.48 vs $0.4002 estimate

Q4-2025: Beat consensus by 13.3% - EPS $0.5 vs $0.4413 estimate

Q2-2025: Beat consensus by 7.0% - EPS $-16 vs $-17.2125 estimate

Beat consensus by 34.6% - EPS $-8 vs $-12.24 estimate

Q1-2025: Beat consensus by 26.5% - EPS $-13 vs $-17.6802 estimate

Q3-2025: Beat consensus by 10.8% - EPS $-13.5 vs $-15.1302 estimate

Beat consensus by 19.0% - EPS $1.16 vs $0.975 estimate

Q3-2025: Beat consensus by 10.6% - EPS $0.97 vs $0.8767 estimate

Q1-2026: Beat consensus by 54.8% - EPS $0.7 vs $0.4523 estimate

5 congress members traded TSCO - net BEAR (0B/0S)

Seagate Technology Holdings plc search volume spiked +100 pts - unusual interest

ABBOTT LABORATORIES search volume spiked +54 pts - unusual interest

OSINT: Market Calendar Update for June 15, 2026

5 congress members traded TSCO - net BEAR (0B/0S)

Seagate Technology Holdings plc search volume spiked +100 pts - unusual interest

ABBOTT LABORATORIES search volume spiked +54 pts - unusual interest

Q4-2026: EPS $0.12 vs $-0.0102 estimate, +0.13 on a near-zero consensus

Q1-2027: EPS $0.10 vs $-0.0408 estimate, +0.14 on a near-zero consensus

OSINT: Belarus Declares No Military Action Against Ukraine

OSINT: S&P 500 jumps 1.7% on US‑Iran deal, adds $1.2 trn market cap

OSINT: Market Calendar Update for June 15, 2026

OSINT: Russia’s Kyiv Drone & Missile Strike Ignites Historic Dovzhenko Film Studio

OSINT: Belarus Declares No Military Action Against Ukraine

OSINT: Belarus Declares No Military Action Against Ukraine

OSINT: S&P 500 jumps 1.7% on US‑Iran deal, adds $1.2 trn market cap

OSINT: US Air Force B‑52 bomber crashes at Edwards AFB, crew status unknown

OSINT: Market Calendar Update for June 15, 2026

OSINT: Market Calendar Update for June 15, 2026

OSINT: Russia’s Kyiv Drone & Missile Strike Ignites Historic Dovzhenko Film Studio

Financial conditions loosening - NFCI at -0.51, liquidity supportive